Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model
Open Access
- 31 January 2013
- journal article
- Published by Springer Science and Business Media LLC in Journal of Translational Medicine
- Vol. 11 (1), 28
- https://doi.org/10.1186/1479-5876-11-28
Abstract
Background The early peritoneal invasion of epithelial ovarian cancer (EOC) by tumoral aggregates presents in ascites is a major concern. The role of the microenvironment seems to be important in this process but the lack of adequate models to study cellular interactions between cancer cells and stromal cells does not allow to uncover the molecular pathways involved. Our goal was to study the interactions between ovarian cancer cells (OCC) and mesenchymal stem cells (MSC) using a 3D model. Methods We used millimetric pieces of amniochorionic membrane - referred to as amniotic membrane scaffold (AMS) - to create 3D peritoneal nodules mimicking EOC early invasion. We were able to measure the distribution and the depth of infiltration using confocal microsopy. We extracted MSC from the amniochorionic membrane using the markers CD34-, CD45-, CD73+, CD90+, CD105+ and CD29+ at the Fluorescence Activated Cell Sorting (FACS) analysis. We used transwell and wound healing tests to test OCC migration and invasion in vitro. Results Here we show that OCC tumors were located in regions rich in MSC (70%). The tumors infiltrated deeper within AMS in regions rich in MSC (p<0.001). In vitro tests revealed that higher IL6 secretion in a context of MSC-OCC co-culture could enhance migration and invasion of OCC. After IL6 receptor antagonism, OCC infiltration was significantly decreased, mostly in regions rich in MSCs, indicating that recruitment and tridimensional invasion of OCC was dependent of IL6 secretion. Conclusions The use of tridimensional models using AMS could be a useful tool to decipher early molecular events in ovarian cancer metastasis. Cytokine inhibitors interrupting the cross-talk between OCCs and MSCs such as IL6 should be investigated as a new therapeutic approach in ovarian cancer.This publication has 39 references indexed in Scilit:
- Comprehensive Characterization of Mesenchymal Stem Cells from Human Placenta and Fetal Membrane and Their Response to Osteoactivin StimulationStem Cells International, 2012
- Tumor Metastasis: Molecular Insights and Evolving ParadigmsCell, 2011
- Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the MesotheliumCancer Discovery, 2011
- Paracrine and Autocrine Signals Induce and Maintain Mesenchymal and Stem Cell States in the BreastCell, 2011
- CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3Cancer Cell, 2011
- Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine NetworksCancer Research, 2011
- Immunity, Inflammation, and CancerCell, 2010
- Hospicells (ascites‐derived stromal cells) promote tumorigenicity and angiogenesisInternational Journal of Cancer, 2009
- The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial–mesenchymal transition in ovarian carcinomasBritish Journal of Cancer, 2008